Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T16:32:07.174Z.
Calculation as of: 2026-10-06T16:32:07.174Z.
Quote observation: 2026-10-06T16:30:39.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b57bdb6cebd2fc5d726de3303ac3337ac80931875060aa84c0ac08143d0f88af
PEG RATIO
N/A
Market Cap
$359.33M
PEG Ratio
N/A
TTM Avg
47.60
3Y Avg
47.60
5Y Avg
23.01
Market Cap
$349.40M
PEG Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Embecta Corp. (EMBC) | $359.53M | N/A | N/A | N/A | N/A |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $359.33M | N/A | 47.60 | 47.60 | 23.01 |
| Ocugen, Inc. (OCGN)vs › | $359.46M | N/A | N/A | N/A | N/A |
| Opus Genetics, Inc. (IRD)vs › | $363.54M | N/A | N/A | N/A | N/A |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $355.36M | N/A | N/A | N/A | N/A |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $354.70M | N/A | N/A | N/A | N/A |
| Relmada Therapeutics, Inc. (RLMD)vs › | $353.30M | N/A | N/A | N/A | N/A |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $349.40M | N/A | N/A | N/A | N/A |
| Canopy Growth Corporation (CGC)vs › | $374.75M | N/A | N/A | N/A | N/A |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $379.76M | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
4.1
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
